Search results

Nonclinical study of JAK1-siRNA in minipigs shows targeted, long-lasting efficacy for inflammatory skin diseases with minimal systemic exposure.

Ken Phares demystifies ICH Q14 & Q2(R2) guidelines with practical strategies for analytical procedure development, risk-based method design, and lifecycle management.

Discover how clinic-ready manufacturing and adaptive clinical trials streamline drug development, prevent delays, conserve your resources, and ensure safety, compliance, and efficiency.

Discover seven tips from expert toxicologist and consultant Robin Guy on tackling key challenges for in vitro NAMs studies, from data integrity to regulatory acceptance.